Effects of sitagliptin on coronary atherosclerosis evaluated using integrated backscatter intravascular ultrasound in patients with type 2 diabetes: rationale and design of the TRUST study

Heart and Vessels
Tsuyoshi NozueIchiro Michishita

Abstract

Patients with diabetes mellitus are at high risk for developing coronary artery disease (CAD), even if they are treated with statins. Several studies have shown the beneficial effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on the cardiovascular system in an animal model. However, recent clinical trials using DPP-4 inhibitors have shown that these inhibitors fail to reduce the occurrence of cardiovascular events. Therefore, this study will be performed to evaluate the effects of sitagliptin, a DPP-4 inhibitor, on coronary atherosclerosis in patients with type 2 diabetes. This study will be a prospective, open-label, randomized multicenter trial performed in 6 centers in Japan. Stable CAD patients with type 2 diabetes who have undergone successful percutaneous coronary intervention under integrated backscatter (IB)-intravascular ultrasound (IVUS) guidance will be studied. They will be randomly assigned to either the sitagliptin group or a control group. After 48 weeks' treatment, the IVUS examination will be repeated in the same coronary artery as at baseline. The primary end point will be the percentage change in plaque volume measured using grayscale IVUS from baseline to the 48-week follow-up. This study will be the firs...Continue Reading

References

Mar 6, 2003·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·Paul SchoenhagenSteven E Nissen
Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Sep 9, 2004·American Journal of Physiology. Endocrinology and Metabolism·Thomas NyströmAke Sjöholm
Mar 10, 2005·The New England Journal of Medicine·John C LaRosaUNKNOWN Treating to New Targets (TNT) Investigators
Jun 10, 2008·The New England Journal of Medicine·UNKNOWN Action to Control Cardiovascular Risk in Diabetes Study GroupWilliam T Friedewald
Jul 19, 2008·Journal of the American College of Cardiology·Stephen J NichollsSteven E Nissen
May 12, 2011·Journal of Cardiovascular Pharmacology·Nga N TaYan Huang
Jul 13, 2012·Circulation Journal : Official Journal of the Japanese Circulation Society·Tsuyoshi NozueUNKNOWN TRUTH Investigators
May 24, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Samuel S EngelBarry J Goldstein
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Nov 20, 2014·Cardiovascular Diabetology·Yuichi TerawakiToshihiko Yanase

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Risk Reduction

Prevention of cardiovascular disease is an important health initiative. Risk reduction including physical activity, smoking cessation, diet, blood pressure lowering drugs and pharmacotherapy. Here is the latest research on cardiovascular risk reduction.